Skip to main content
Erschienen in: Neurological Sciences 2/2011

01.04.2011 | Brief Communication

Serum uric acid levels in multiple sclerosis patients inversely correlate with disability

verfasst von: A. L. Guerrero, F. Gutiérrez, F. Iglesias, J. Martín-Polo, S. Merino, J. I. Martín-Serradilla, E. Laherrán, M. A. Tejero

Erschienen in: Neurological Sciences | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Uric acid (UA) is an endogenous antioxidant. Some studies have described that multiple sclerosis (MS) patients have lower serum UA levels than controls, although it has not been established whether UA is primarily deficient, or secondarily reduced due to its scavenging activity. UA has also been proposed as an indicator of disease activity. We, retrospectively, reviewed 478 serum UA levels obtained in 94 MS patients. Ninety samples were collected during a relapse. Correlation between UA levels obtained during a relapse or in a relapse-free period, and comparison between UA and expanded disability status scale (EDSS) score was tested using a two-tailed Student’s t test and Spearman correlation coefficients test. UA levels were significantly lower when measured during a relapse (n 90) than in a remission period (n 368) (r −0.16, p 0.003) UA levels measured outside a relapse inversely correlated with EDSS score (r −0.15, p 0.001). Lower uric acid levels in MS patients are associated with clinical relapse. This is the first description of an inverse correlation of serum UA levels with disability as assessed by EDSS score.
Literatur
1.
Zurück zum Zitat Scott GS, Spitsin SV, Kean RB, Mikheeva T, Koprowski H, Hooper DC (2002) Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. Proc Natl Acad Sci USA 99(25):16303–16308PubMedCrossRef Scott GS, Spitsin SV, Kean RB, Mikheeva T, Koprowski H, Hooper DC (2002) Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. Proc Natl Acad Sci USA 99(25):16303–16308PubMedCrossRef
2.
Zurück zum Zitat Touil T, Deloire-Grassin MS, Vital C, Petry KG, Brochet B (2001) In vivo damage of CNS myelin and axons induced by peroxynitrite. Neuroreport 12(16):3637–3644 Touil T, Deloire-Grassin MS, Vital C, Petry KG, Brochet B (2001) In vivo damage of CNS myelin and axons induced by peroxynitrite. Neuroreport 12(16):3637–3644
3.
Zurück zum Zitat Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM, Chaudhry I et al (1998) Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 95(2):675–680PubMedCrossRef Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM, Chaudhry I et al (1998) Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 95(2):675–680PubMedCrossRef
4.
Zurück zum Zitat Toncev G, Milicic B, Toncev S, Samardzic G (2002) Serum uric acid levels in multiple sclerosis patiens correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol 9:221–226PubMedCrossRef Toncev G, Milicic B, Toncev S, Samardzic G (2002) Serum uric acid levels in multiple sclerosis patiens correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol 9:221–226PubMedCrossRef
5.
Zurück zum Zitat Drulovic J, Dujmovic I, Stojsavljevic N, Mesaros S, Andjelkovic S, Miljkovic D et al (2001) Uric acid levels in sera from patients with multiple sclerosis. J Neurol 248(2):121–126PubMedCrossRef Drulovic J, Dujmovic I, Stojsavljevic N, Mesaros S, Andjelkovic S, Miljkovic D et al (2001) Uric acid levels in sera from patients with multiple sclerosis. J Neurol 248(2):121–126PubMedCrossRef
6.
Zurück zum Zitat Scott GS, Hooper DC (2001) The role of uric acid in protection against peroxynitrite-mediated pathology. Med Hypotheses 56(1):95–100PubMedCrossRef Scott GS, Hooper DC (2001) The role of uric acid in protection against peroxynitrite-mediated pathology. Med Hypotheses 56(1):95–100PubMedCrossRef
7.
Zurück zum Zitat Mostert JP, Ramsaransing GSM, Heersema DJ, Heerings M, Wilczak N, De Keyser J (2005) Serum uric acid levels and leukocyte nitric oxide production in multiple sclerosis patients outside relapses. J Neurol Sci 231:41–44PubMedCrossRef Mostert JP, Ramsaransing GSM, Heersema DJ, Heerings M, Wilczak N, De Keyser J (2005) Serum uric acid levels and leukocyte nitric oxide production in multiple sclerosis patients outside relapses. J Neurol Sci 231:41–44PubMedCrossRef
8.
Zurück zum Zitat Karg E, Klivenyi P, Nemeth I, Bencsik K, Pinter S, Vecsei L (1999) Nonenzymatic antioxidants of blood in multiple sclerosis. J Neurol 246:533–539PubMedCrossRef Karg E, Klivenyi P, Nemeth I, Bencsik K, Pinter S, Vecsei L (1999) Nonenzymatic antioxidants of blood in multiple sclerosis. J Neurol 246:533–539PubMedCrossRef
9.
Zurück zum Zitat Ramsaransing GSM, Heersema DJ, De Keyser J (2005) Serum uric acid, dehydroepiandrosterone sulphate, and apolipoprotein E genotype in benign vs progressive multiple sclerosis. Eur J Neurol 12:514–518PubMedCrossRef Ramsaransing GSM, Heersema DJ, De Keyser J (2005) Serum uric acid, dehydroepiandrosterone sulphate, and apolipoprotein E genotype in benign vs progressive multiple sclerosis. Eur J Neurol 12:514–518PubMedCrossRef
10.
Zurück zum Zitat Peng F, Zhong X, Deng X, Qiu W, Wu A, Long Y et al (2010) Serum uric acid levels and neuromyelitis optica. J Neurol 257:1021–1026PubMedCrossRef Peng F, Zhong X, Deng X, Qiu W, Wu A, Long Y et al (2010) Serum uric acid levels and neuromyelitis optica. J Neurol 257:1021–1026PubMedCrossRef
11.
Zurück zum Zitat Salemi G, Gueli MC, Vitale F, Battaglieri F, Guglielmini E, Ragonese P et al (2010) Blood lipids, homocysteine, stress factors, and vitamins in clinically stable multiple sclerosis patients. Lipids Health Dis 9:19–21PubMedCrossRef Salemi G, Gueli MC, Vitale F, Battaglieri F, Guglielmini E, Ragonese P et al (2010) Blood lipids, homocysteine, stress factors, and vitamins in clinically stable multiple sclerosis patients. Lipids Health Dis 9:19–21PubMedCrossRef
12.
Zurück zum Zitat Massa J, O’Reilly E, Munger KL, Delorenze GN, Ascherio A (2009) Serum uric acid and risk of multiple sclerosis. J Neurol 256:1643–1648PubMedCrossRef Massa J, O’Reilly E, Munger KL, Delorenze GN, Ascherio A (2009) Serum uric acid and risk of multiple sclerosis. J Neurol 256:1643–1648PubMedCrossRef
13.
Zurück zum Zitat Amorini AM, Petzold A, Tavazzi B, Eikelenboom J, Keir G, Belli A et al (2009) Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. Clin Biochem 42:1001–1006PubMedCrossRef Amorini AM, Petzold A, Tavazzi B, Eikelenboom J, Keir G, Belli A et al (2009) Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. Clin Biochem 42:1001–1006PubMedCrossRef
14.
Zurück zum Zitat Sotgiu S, Pugliatti M, Sanna A, Sotgiu A, Fois ML, ARRU G et al (2002) Serum uric acid and multiple sclerosis. Neurol Sci 23(4):183–188PubMedCrossRef Sotgiu S, Pugliatti M, Sanna A, Sotgiu A, Fois ML, ARRU G et al (2002) Serum uric acid and multiple sclerosis. Neurol Sci 23(4):183–188PubMedCrossRef
15.
Zurück zum Zitat Peng F, Zhang B, Zhong X, Li J, Xu G, Hu X et al (2008) Serum uric acid levels of patients with multiple sclerosis and other neurological diseases. Mult Scler 14:188–196PubMedCrossRef Peng F, Zhang B, Zhong X, Li J, Xu G, Hu X et al (2008) Serum uric acid levels of patients with multiple sclerosis and other neurological diseases. Mult Scler 14:188–196PubMedCrossRef
16.
Zurück zum Zitat Toncev G, Milicic B, Toncev S, Samardzic G (2002) High-dose methylprednisolone theraphy in multiple sclerosis increases serum uric acid levels. Clin Chem Lab Med 40:505–508PubMedCrossRef Toncev G, Milicic B, Toncev S, Samardzic G (2002) High-dose methylprednisolone theraphy in multiple sclerosis increases serum uric acid levels. Clin Chem Lab Med 40:505–508PubMedCrossRef
17.
Zurück zum Zitat Guerrero AL, Martín-Polo J, Laherrán E, Gutiérrez F, Iglesias F, Tejero MA et al (2008) Variation of serum uric acid levels in multiple sclerosis during relapses and immunomodulatory treatment. Eur J Neurol 15:394–397PubMedCrossRef Guerrero AL, Martín-Polo J, Laherrán E, Gutiérrez F, Iglesias F, Tejero MA et al (2008) Variation of serum uric acid levels in multiple sclerosis during relapses and immunomodulatory treatment. Eur J Neurol 15:394–397PubMedCrossRef
18.
Zurück zum Zitat Constantinescu CS, Freitag P, Kappos L (2000) Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with Glatiramer acetate for multiple sclerosis. Mult Scler 6:378–381PubMed Constantinescu CS, Freitag P, Kappos L (2000) Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with Glatiramer acetate for multiple sclerosis. Mult Scler 6:378–381PubMed
19.
Zurück zum Zitat Kanabrocki EL, Ryan MD, Hermida RC, Ayala DE, McCormick JB, Dawson S et al (2008) Uric acid and renal function in Multiple Sclerosis. Clin Ter 159:35–40 Kanabrocki EL, Ryan MD, Hermida RC, Ayala DE, McCormick JB, Dawson S et al (2008) Uric acid and renal function in Multiple Sclerosis. Clin Ter 159:35–40
20.
Zurück zum Zitat Gonsette RE, Sindic C, D′hooghe MB, De Deyn PP, Medaer R, Michotte A et al (2010) Boosting endogenous neuroprotection in multiple sclerosis: the association of inosine and interferon beta in relapsing-remitting multiple sclerosis (ASIIMS) trial. Mult Scler 16:455–462PubMedCrossRef Gonsette RE, Sindic C, D′hooghe MB, De Deyn PP, Medaer R, Michotte A et al (2010) Boosting endogenous neuroprotection in multiple sclerosis: the association of inosine and interferon beta in relapsing-remitting multiple sclerosis (ASIIMS) trial. Mult Scler 16:455–462PubMedCrossRef
Metadaten
Titel
Serum uric acid levels in multiple sclerosis patients inversely correlate with disability
verfasst von
A. L. Guerrero
F. Gutiérrez
F. Iglesias
J. Martín-Polo
S. Merino
J. I. Martín-Serradilla
E. Laherrán
M. A. Tejero
Publikationsdatum
01.04.2011
Verlag
Springer Milan
Erschienen in
Neurological Sciences / Ausgabe 2/2011
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-011-0488-5

Weitere Artikel der Ausgabe 2/2011

Neurological Sciences 2/2011 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.